Skip to main content

A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination with Enzalutamide in Subjects with Metastatic Castrate-Resistanct Prostate Cancer

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Gilead Sciences, Inc.

Start Date

April 1, 2016

End Date

December 8, 2020
 

Administered By

Duke Cancer Institute

Awarded By

Gilead Sciences, Inc.

Start Date

April 1, 2016

End Date

December 8, 2020